MFMaryam Farasatinasab

Maryam Farasatinasab

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Maryam Farasatinasab has a total of 130 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Trimethoprim‐Sulfamethoxazole in the Treatment of Idiopathic Granulomatous Mastitis: A Retrospective Cohort Study

    by Soheila Sayad, Saba Ahmadi, Mahdi Ahmadinia, Azadeh Eshraghi, Hamidreza Aslani, Maryam Farasatinasab

    Background and Aims: Idiopathic Granulomatous Mastitis (IGM) is a rare, chronic inflammatory breast condition with uncertain etiology and challenging management. Standard treatments often involve corticosteroids or surgery, both associated with significant relapse and adverse effects. Recent interest has emerged in using antibiotics such as Trimethoprim‐Sulfamethoxazole (TMP‐SMX) due to potential antimicrobial and anti‐inflammatory benefits, though evidence remains limited. Methods: This retrospective cohort study evaluated the effectiveness and safety of TMP‐SMX compared to conventional therapies in female patients diagnosed with histologically confirmed IGM. Patients were categorized into the TMP‐SMX and control groups. Primary outcomes included treatment response and recurrence rates; secondary outcomes assessed changes in lesion size, clinical severity, and adverse events. Statistical analyzes included Chi‐square, Fisher's exact test, and odds ratios (ORs) with 95% confidence intervals. Results: Complete clinical remission was achieved in 70.8% of TMP‐SMX ( N = 24) patients versus 51.2% in the control ( N = 43) group ( p = 0.12). Recurrence rates were comparable between groups (37.5% in the TMP‐SMX group vs. 27.9% in the control group, p = 0.51). TMP‐SMX patients showed trends toward reduced lesion size and milder disease, although differences were not statistically significant. Adverse events were less frequent in the TMP‐SMX group, except for transient fatigue ( p = 0.04). Conclusion: This study provides evidence that TMP‐SMX is a safe and clinically effective alternative to corticosteroid‐based regimens for managing idiopathic IGM. TMP‐SMX demonstrated comparable efficacy, including favorable trends in lesion regression and disease severity improvement, with notably fewer systemic adverse events.

  • Correction: Efficacy and safety of colistin–doxycycline combination therapy in multi-drug resistance Gram-negative infections: a double-blind randomized controlled trial

    by Shaghayegh Abaft, Zeynab Yassin, Mahdi Ahmadinia, Azadeh Eshraghi, Behnaz Gholizadeh Niari, Sara Minaeian, Maryam Farasatinasab

  • Open Access

    Translational immunothrombosis in autoimmune Heparin-Induced thrombocytopenia: targeting the FcγRIIa–Syk–BTK and complement pathways

    by Mahdi Ahmadinia, Abolfazl Askarzade, Hanif Afsharara, Behnaz Gholizadeh Niari, Faezeh Jamali, Maryam Farasatinasab

    Autoimmune heparin-induced thrombocytopenia (aHIT) represents a severe variant of immune-mediated thrombocytopenias (IMTs) in which anti-platelet factor 4 (PF4) antibodies activate platelets independently of heparin, leading to both thrombosis and thrombocytopenia. Despite its clinical significance, aHIT remains poorly understood and lacks evidence-based immunomodulatory treatments. This narrative translational review integrates mechanistic and therapeutic insights from immune thrombocytopenia (ITP) and antiphospholipid syndrome (APS) to identify shared pathogenic pathways relevant to aHIT. Literature from 2015 to 2025 was analyzed across PubMed, Scopus, Web of Science, and ClinicalTrials.gov, focusing on FcγRIIa–Syk–BTK signaling and complement activation as central drivers of platelet activation and clearance. Preclinical and clinical data indicate that targeting these axes with Syk inhibitors (fostamatinib), BTK inhibitors (rilzabrutinib, zanubrutinib), and complement inhibitors (sutimlimab) can restore platelet counts and mitigate immune-driven thrombosis. These findings underscore the therapeutic potential of pathway-specific interventions in aHIT, highlighting the need for biomarker-guided, translational trials to validate their efficacy and safety. Bridging mechanistic evidence from ITP and APS provides a framework for precision immunotherapy in autoimmune HIT.


  • Efficacy and safety of colistin–doxycycline combination therapy in multi-drug resistance Gram-negative infections: a double-blind randomized controlled trial

    by Shaghayegh Abaft, Zeynab Yassin, Mahdi Ahmadinia, Azadeh Eshraghi, Behnaz Gholizadeh Niari, Sara Minaeian, Maryam Farasatinasab, Zeinab Yasin

    Background & objectives Multidrug-resistant (MDR) Klebsiella pneumoniae poses a critical treatment challenge. Colistin remains a last-resort antibiotic but is limited by nephrotoxicity and resistance. Though clinical data are limited, Doxycycline has demonstrated in vitro synergy with colistin. Colistin–meropenem is frequently used as a comparator regimen, despite mixed evidence on its synergistic activity. This study evaluates the efficacy, microbiological response, and safety of colistin–doxycycline versus colistin–meropenem in MDR Gram-negative infections. Methods A double-blind, randomized controlled trial was conducted at a teaching hospital. Adult patients with culture-confirmed MDR Klebsiella pneumoniae infections were randomized to receive colistin–doxycycline or colistin–meropenem. The primary outcome was clinical cure, defined as resolution of infection signs without therapy escalation and in-hospital mortality. Secondary outcomes included microbiological eradication, acute kidney injury (AKI), and treatment-related adverse events. Patients were followed throughout hospitalization and for 14 days post-treatment. Results A total of 46 patients were enrolled, with 23 patients in each group. Clinical cure rates were significantly higher in the colistin–doxycycline group (87.0% vs. 46.7%, p = 0.012), and mortality was lower (69.6% vs. 86.7%, p = 0.017). Microbiological eradication was also superior (p = 0.016), and nephrotoxicity incidence was numerically lower (19.1% vs. 33.3%, p = 0.092). Faster resolution of inflammation (p < 0.05) and reduced need for mechanical ventilation (60.9% vs. 33.3%, p = 0.028) were observed in the colistin–doxycycline group. Conclusions Colistin–doxycycline showed superior efficacy to colistin–meropenem in MDR Klebsiella pneumoniae infections, with higher cure rates, better bacterial eradication, and a favorable safety trend. These results support its potential as a possible alternative option in managing MDR Gram-negative infections, though confirmation in larger multicenter trials is needed. Graphical abstract


  • Open Access

    Community Pharmacy Dispensing Errors: A Comprehensive Systematic Review on Trends and Solutions

    by Azadeh Eshraghi, Niloofar Madani, Hamidreza Aslani, Maryam Farasatinasab

    Dispensing errors in outpatient and community pharmacies pose significant safety risks and contribute to increased global healthcare costs. Despite their frequency, comprehensive studies on rates, causes, and interventions remain limited. This review examines current evidence on dispensing error prevalence, key risk factors, and the impact of mitigation strategies. Following PRISMA guidelines, we systematically searched PubMed, Embase, and CINAHL for studies on dispensing error rates in community and outpatient pharmacies, covering the period from January 2010 to June 2025, including English-language studies and grey literature. Eligible studies reported calculable prevalence using cross-sectional, cohort, or longitudinal designs. Two reviewers independently assessed records, extracted data, and evaluated bias using the NHLBI and Grading of Recommendations Assessment, Development, and Evaluation (GRADE) tools. In 22 studies (13 from developing, 9 from developed countries), dispensing error rates ranged from 0.001% to 11.53%, higher in community (mean 4.12%) than in outpatient pharmacies (1.85%). Common errors were wrong dose/ strength (58.6%) and look-/sound-alike drugs (47.90%). Key contributors were workload (55%), staff shortages (22%), and illegible prescriptions (30.70%). While one study reported a modest 1.40% decrease with electronic prescribing, another observed up to a 98.20% reduction using automated systems. GRADE evaluation found very low confidence in the data due to variability in study settings and methods. Dispensing errors remain a major issue, particularly in community pharmacies and underserved areas. Multimodal strategies – integrating technology, standardizing workflows, and training staff – represent a potentially effective approach to reducing errors. Although the certainty of the evidence is very low, the findings may still help guide future policies aimed at introducing error reporting systems, adopting technology, and improving consistency in research methods.


  • Open Access

    Prevalence and types of medication errors in pro re nata medication orders among hospitalized patients: a cross-sectional study

    by Arefeh Rasouli-Rad, Mahdi Ahmadinia, Azadeh Eshraghi, Hamidreza Aslani, Zahra Karimian, Akram Hashemi, Maryam Farasatinasab

    Background: Medication errors in Pro Re Nata (PRN) prescriptions pose a significant threat in hospital settings, especially due to unclear prescribing practices. Despite growing attention to patient safety, documentation for PRN orders remains poor, increasing the risk of medication errors and adverse drug events. To assess the prevalence and types of PRN medication errors in hospitalized patients, identify high-risk drugs, and explore factors linked to prescribing errors. Methods: This cross-sectional study was conducted in 2023 at an Educational and Research Hospital. It included 400 hospitalized patients who had received at least one PRN prescription. Data were collected using a standardized extraction form based on clinical guidelines and expert consultation. Chi-square tests and logistic regression were used to evaluate error trends and associated risk factors. Results: A total of 74.1% of PRN prescriptions lacked a documented indication, and 91.1% had no recorded dosage interval. Pethidine (32.6%) was the most frequently prescribed PRN medication. The Surgical ICU showed a significantly higher number of errors ( p < 0.05). Major predictors of PRN errors included missing dosage intervals and admission to high-dependency wards. Conclusions: The high frequency of PRN prescribing errors underscores the urgent need for improved documentation and targeted training. Structured interventions such as electronic prescribing and focused medical education can help reduce errors and improve patient safety. Structured interventions such as electronic prescribing, regulatory enforcement, and focused medical education can help reduce errors and improve patient safety.

  • Open Access

    The Positive Effects of Colchicine Against Inflammatory Cytokines in Patients After Acute MI: A Randomized Clinical Trial Study

    by Seyyed Ali Banifatemeh, Marjan Hajahmadi, Somayyeh Nasiripour, Maryam Farasatinasab, Niki Deihim, Seyyedeh Mina Hejazian, Maryam Dahmardeh, Seyyedeh Mina Mostafavi Montazeri, Saeed Sadr, Soroush Mostafavi

    Background: Inflammatory responses initiate immediately after acute myocardial infarction (MI). Colchicine, known for its anti-inflammatory properties, is used to treat inflammatory diseases. Objectives: The present study aimed to evaluate inflammatory responses among patients with acute MI following the administration of colchicine. Methods: This randomized double-blinded clinical trial included adult patients with acute MI (n = 81), determined via an arbitrary approach, who were randomly divided into intervention (n = 41) and control (n = 40) groups using random allocation software. The study subjects included all referred adult MI patients (aged 18 to 80 years) with ST-elevation myocardial infarction (STEMI) and presentation of chest pain onset for at least 12 hours. Patients received the intervention (colchicine/placebo 3 mg) at the beginning of primary percutaneous coronary intervention (PCI) and one hour thereafter. Inflammatory factors, including C-reactive protein (CRP), interleukin-1β (IL-1β), and IL-6, along with clinical data such as systolic blood pressure (SBP), diastolic blood pressure (DBP), and heart rate (HR), were recorded at the end of the study. Data were analyzed using SPSS version 23 software, with a P-value ≤ 0.05 considered statistically significant. Results: The results showed that CRP levels, along with SBP, DBP, and HR, in both control and intervention groups were significantly decreased compared to baseline levels (P < 0.001). Moreover, there was a significant reduction in CRP and IL-1β levels in the intervention group compared to the control group after the intervention (P = 0.001). Conclusions: Our study demonstrated that two dosages of colchicine decreased inflammatory responses after PCI in patients with acute MI. However, its effects on blood pressure need to be investigated over a longer period, considering confounding factors.


  • Variable Levels of Oxytocin During Sepsis: The Role of Oxytocin in Sepsis Pathophysiology

    by Mahdi Yadollahzadeh, Nader Rezaie, Mohana Eskandari, Mohsen Farrokhpour, Mehdi Azimi, Maryam Farasatinasab

    Background: Although the role of oxytocin in the pathophysiology of sepsis is still unknown, rising preclinical evidence suggests that oxytocin is possibly involved. However, no direct clinical studies have measured the levels of oxytocin during sepsis. In this preliminary study, the serum oxytocin levels were evaluated throughout the duration of sepsis. Method: Twenty-two male patients over 18 years of age with a SOFA score of 2 points or more who were admitted to the ICU were included. Patients with a history of neuroendocrine, psychiatric, and neurologic disorders, cancer, an infection caused by COVID-19, shock due to reasons other than sepsis, a history of psychiatric or neurologic medication use, and those who died during the study were excluded. The main endpoint included the measurement of serum oxytocin levels using radioimmunoassay at 6, 24, and 48 h of the ICU admission. Results: Mean serum oxytocin level was higher at 6 h of ICU admission (41.27 ± 13.14 ng/L) than after 24 and 48 h of ICU admission (22.63 ± 5.75 and 20.97 ± 7.61 ng/L respectively) ( P-value < .001). Conclusion: Our study, while reporting increased serum oxytocin levels in the initial phase of sepsis and decline afterward, supports the possible contribution of oxytocin in the pathophysiology of sepsis. Given that oxytocin seems to modulate the innate immune system, future investigations are necessary to assess the potential role of oxytocin in the pathophysiology of sepsis.


  • Surviving surgery; succumbing to pharmacotherapy: A case report underscoring the importance of PRN order clarification for patient safety

    by Setare Nassiri, Zahra Karimian, Kobra Tahermanesh, Maryam Farasatinasab

    “Pro re nata” (PRN) or “as needed” medicine administration and usage is a relatively neglected area in medication management (pharmacotherapy/pharmaceutical care) which contributes to error‐prone use of medications and is unsafe for patients. In this case, we report the incident of diclofenac toxicity in a 51‐year‐old woman due to a prescription of 100 mg diclofenac suppositories PRN, or as needed, for postoperative pain control without explanation of the maximum daily dose (150 mg daily), which led to arbitrary consumption of 3 g of diclofenac over 5 days (600 mg daily) by the patient, and subsequent development of metabolic acidosis, acute kidney injury, and sudden cardiac arrest. The implementation of practical guidelines and training programs for health care workers to appropriately prescribe, dispense, and administer PRN medicines are necessary, and should at least include providing clarification for their indication, dose and frequency, as well as any cautionary instructions to ensure safe and effective use of such medicines.

  • Open Access

    Effect of cannabis use on propofol requirement for ICU sedation

    by Maryam Farasatinasab, Somayyeh Nasiripour, Abbas Aghabiklooei